title: [Management of severe alcoholic hepatitis].
abstract: Severe alcoholic hepatitis is still associated with high mortality and presence of liver failure manifested by jaundice, coagulopathy and encephalopathy is a poor prognostic indicator. The management of these patients includes at first hand several supportive measures as treatment of alcohol withdrawal, administration of fluid and vitamins and admission to an intensive care unit in the unstable patient. Glucocorticoids have been since decades the most intensively studied therapy in alcoholic hepatitis and are effective in certain subgroups. Indication for such a therapy is usually defined on a Maddrey Discriminant Function > 32. The Lille score at day 7 is used to decide whether corticosteroid therapy should be stopped or continued for a 1 month course. Nutritional supplementation is also likely to be beneficial. The main progress in better understanding its pathophysiology has come from cytokine studies. Various proinflammatory cytokines such as tumor necrosis factor-alpha (TNFα) or interleukin-1 (IL-1) have been proposed to play a role in this disease. This advancement has recently led to pilot studies investigating anti-TNF drugs such as pentoxifylline, infliximab (anti-TNF antibody) or etanercept in the treatment of this disease. These studies revealed besides for pentoxifylline rather negative results. Despite this fact, targeting of certain cytokines such as IL-1 remains an attractive treatment concept for this devastating disorder in the future.
authors.affiliation: Univ.-Klinik für Innere Medizin I, Endokrinologie, Gastroenterologie & Stoffwechsel, Medizinische Universität, Anichstrasse 35, 6020, Innsbruck, Austria, Verena.Wieser@i-med.ac.at.
authors.forename: Verena
authors.initials: V
authors.lastname: Wieser
authors.forename: Herbert
authors.initials: H
authors.lastname: Tilg
mesh_terms: D000437:Alcoholism / Q000503:physiopathology / Q000534:rehabilitation; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000068800:Etanercept; D005235:Fatty Liver, Alcoholic / Q000175:diagnosis / Q000503:physiopathology / Q000534:rehabilitation; D005440:Fluid Therapy; D005938:Glucocorticoids / Q000008:administration & dosage; D006519:Hepatitis, Alcoholic / Q000175:diagnosis / Q000503:physiopathology / Q000534:rehabilitation*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D000069285:Infliximab; D007362:Intensive Care Units; D007375:Interleukin-1 / Q000097:blood; D017114:Liver Failure, Acute / Q000175:diagnosis / Q000503:physiopathology / Q000534:rehabilitation; D008111:Liver Function Tests; D016031:Liver Transplantation; D018579:Patient Selection; D010431:Pentoxifylline / Q000008:administration & dosage; D010865:Pilot Projects; D011379:Prognosis; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood; D014815:Vitamins / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D014815:Vitamins; D000069285:Infliximab; D000068800:Etanercept; D010431:Pentoxifylline